• Guillemette Fouquet, Claire Bories, Stéphanie Guidez, Loïc Renaud, Charles Herbaux, Sahir Javed, Thierry Facon, and Xavier Leleu.
• Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M. Polonovski, 59037 Lille, France.
• Expert Rev Hematol. 2014 Dec 1; 7 (6): 719-31.

AbstractOnce characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of 'novel agents': proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide). However, the vast majority - if not all - of patients with MM ultimately end up being refractory to all existing drugs, including these efficient novel agents. There is a clear unmet medical need in this situation, which warrants the development of the next generation of proteasome inhibitors and IMiDs, as well as new drug classes. This drug profile focuses on pomalidomide, the next generation IMiD, recently approved by the US FDA and the EMA for patients with relapsed or refractory MM who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on their last therapy.

35 keywords...

hide…